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Primary meningeal rhabdomyosarcoma is a rare primary brain malignancy, with scant case reports. While most reports of
primary intracranial rhabdomyosarcoma occur in pediatric patients, a handful of cases in adult patients have been reported in
the medical literature. We report the case of a 44-year-old male who developed primary meningeal rhabdomyosarcoma. After
developingepisodesofright lowerextremity weakness,wordﬁndingdiﬃculty,andheadaches,abrainmagneticresonanceimaging
(MRI) demonstrated a vertex lesion with radiographic appearance of a meningeal-derived tumor. Subtotal surgical resection was
performedduetosagittalsinusinvasionandinitialpathologywasinterpreted asananaplasticmeningioma.Re-review ofpathology
demonstratedrhabdomyosarcomanegative foralveolartranslocationt(2;13).Stagingstudies revealed no evidence ofdisseminated
disease.Hewastreated withstereotactic radiotherapywithconcurrenttemozolamidetobefollowedbyvincristine,actinomycin-D,
and cyclophosphamide(VAC) systemic therapy.
1.CasePresentation
The patientwas a44-year-old Caucasian malewith no signif-
icant past medical history who initially experienced episodes
of right lower extremity weakness lasting 2-3 minutes that
ﬁrst occurred in June 2010. He had 2 such episodes in early
June and within a few weeks was experiencing 5-6 episodes
weekly. Shortly thereafter he noticed impairment in ﬁne
motor skills of the right leg with inability to put on shoes,
word-ﬁnding diﬃculty, and severe headaches that awoke
him from sleep. He was seen by his primary care physician,
and MRI demonstrated a 2.7 × 2.5 × 3.1cm brain lesion
arising from the meninges (Figure 1). He was informed of
theimaging resultsand thefollowing daydevelopeda seizure
that started focally in his right arm and leg before becoming
generalized.
He was evaluated in the emergency room and admitted
to the hospital for further evaluation and management.
Surgical resection was performed July 2010 with pathology
initially interpreted as an anaplastic meningioma. Complete
resection was not possible given extensive invasion into the
sagittal sinus. Postoperatively, the patient reported right-
sided motor impairment that improved dramatically with
physical therapy. His headaches and word-ﬁnding diﬃculty
resolved completely postoperatively, and he was discharged
from the hospital on postoperative day no.3. A brain
MRI obtained 10 days following surgery showed a left
frontoparietal vertex resection cavity measuring 2 × 1.5cm
with enhancement anteriorly and posteriorly.
He presented to our institution for an opinion regarding
further therapy. On exam, he was noted to have right upper
and lower extremity weakness and wide-based gait with
right foot drop. Pending review of pathology, we tentatively
recommended highly conformal radiotherapy. Pathologic
review conﬁrmed a high-grade sarcoma consistent with
rhabdomyosarcoma (Figure 2). Tumor cells were found to
express myoD1 (Figure 3), desmin (Figure 4), and myo-
globin. There was no evidence of meningothelial, glial,
or neuronal component. Fluorescence in situ hybridization
was performed, and the typical gene rearrangement (t2:13)
seen in alveolar rhabdomyosarcoma was not visualized.
Additional staging studies, including PET imaging, spine2 Sarcoma
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MRI, bone marrow biopsy, and lumbar puncture, were
obtained, showing no evidence of metastatic disease.
After generating a variety of radiotherapy plans, a vol-
umetric modulated arc therapy (VMAT) plan utilizing a
Novalis Tx linear accelerator system (Varian Palo Alto,
Calif,USAand BrainLAB,Munich, Germany) was ultimately
selected in ordertomaximize targetcoveragewhile minimiz-
ing normal tissue toxicity.In addition, we oﬀeredconcurrent
temozolomide as a radiosensitizer [1]. The primary target
volume encompassed contrast-enhancing tumor on T1-
weighted preoperative MRI, uniformly expanded by 5mm
and further customized to extend 2-3mm further along the
meninges in all directions. The boost volume included the
resection cavity, including areas of anterior and posterior
postoperative enhancement on MRI, with 3mm expansion
and was customized to extend along the meninges in all
directions. We prescribed 5040cGy in 180cGy fractions to
the primary target volume followed by an additional 900cGy
boost in 180cGy fractions to a total dose of 5940cGy.
The blue- and green-shaded volumes represent the primary
and boost volumes, respectively. The thickened yellow and
cyan lines signify the 5040cGy and 5940cGy isodose lines,
respectively (Figure 5). Critical normal tissues, including the
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brainstem, optic chiasm, optic nerves, and eyes all received
minimal dose.
The patient tolerated chemoradiation well. Aside from
mild fatigue, he developed headaches during treatment
which improved with a low dose of steroids that was
gradually tapered. Blood counts remained stable throughout
radiotherapy. At the conclusion of chemoradiotherapy, the
patient began systemic therapy, consisting of vincristine,
actinomycin-D, and cyclophosphamide (VAC) per standard
treatment for rhabdomyosarcoma.
2.LiteratureReview
Rhabdomyosarcoma, the most common pediatric soft tissue
sarcoma, has a predilection for the head and neck, geni-
tourinary organs, and extremities [2]. The mean incidence
of primary brain sarcomas is roughly 3% [3]. Among these
few primary brain sarcomas, 70% arise in the pediatric
population and there have been limited cases reported in
adults [4]. These small numbers may be due, in part,
to histological and anatomic uncertainty. Meningeal rhab-
domyosarcomas must be distinguished from medullomy-
oblastoma, gliosarcoma, and teratomatous germ cell tumors
all of which can have rhabdomyoblastic diﬀerentiation [5].
Although the meninges are composed of both mesenchymal
and neuroectodermal cell lineages, it is the pluripotent
mesenchymal cells that appear to give rise to meningealSarcoma 3
Isodoses (cGy)
5940
5040
4000
3000
1500
6103.1 cGy
A
P
(a)
6352.2 cGy
(b)
Figure 5
rhabdomyosarcomas. This is in contrast to intracranial
rhabdomyosarcomas which more likely arise from the brain
substance and extend to the meninges [6].
Staging with lumbar puncture and imaging is important
for identiﬁcation of all sites of disease. Lumbar puncture or
imaging of the craniospinal axis can identify leptomeningeal
or multifocal disease which can have implications on radio-
therapy ﬁelds and total dose. Few cases have reported diﬀuse
meningeal involvement, but it is associated with a poorer
prognosis [7, 8]. In addition, an extracranial primary site
should be excluded with CT or PET imaging.
Once histological diagnosis and staging is preformed,
there is still much debate regarding appropriate further
treatment. A review of published literature identiﬁed 38
previously reported cases of intracranial rhabdomyosarcoma
with a mean survival of 9.1 months [9]. In this series, most
cases were managed with surgical resection, when feasible,
and22ofthe38patientsreceivedadjuvantradiotherapywith
total dose range from 2500 to 8200cGy. In cases of local-
ized disease, extrapolation of data from the International
Rhabdomyosarcoma Study Group (IRSG) has been applied
[10]. In this study of parameningeal rhabdomyosarcoma,
it was recommended that radio therapy be delivered to
the primary site, the adjacent meninges, and region of
intracranial extension with an appropriate margin, omitting
treatmenttotheentirebrainorspinalaxiswhichisassociated
with heightened toxicity.
The inherent diﬃculty in discerning the cell of origin
in rhabdomyosarcoma makes the selection of appropriate
chemotherapy diﬃcult and usefulness debatable. In the
review by Celli et al., chemotherapy was administered in 11
of 38 cases reported but given heterogeneity of treatments
little could be determined regarding relative eﬀectiveness.
Recent case reports have implemented the use of VAC
chemotherapy which is standard inthe treatment ofsystemic
rhabdomyosarcoma [11].
Our patient represents one of the few adults with
primary meningeal rhabdomyosarcoma. Given the rarity of
these tumors, a multidisciplinary approach is imperative.
While maximal safe surgical resection followed by adjuvant
radiotherapy and chemotherapy is a logical approach to
maximize long-term survival, further study is required to
identify an optimal therapeutic strategy.
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